NCT00540241已完成不适用
Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 542
- 试验地点
- 1
研究概览
简要总结
The primary research objective of this observational study in pretreated patients with NSCLC of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second cycle of second-line treatment with single agent pemetrexed in a real life setting, and to evaluate factors potentially influencing performance status in terms of KI, i.e. frequency of use of concomitant medications, in particular analgesics, folic acid, Vitamin B12, antiemetics, and medications against diarrhea; as documented in patient diary (days of use per week) and by the physicians.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are 18 years of age or older
- •Have NSCLC, Stage IIIa/b or IV, that is not amenable to curative therapy
- •Have had one prior chemotherapy regimen with cytotoxic agents for the treatment of NSCLC (patients with adjuvant and neoadjuvant regimens are also eligible. However, patients with one prior cytotoxic chemotherapy followed by a targeted agent such as erlotinib are not eligible because the targeted agent would be regarded as second-line treatment)
- •Are initiating second-line of treatment for NSCLC with pemetrexed
- •Have been fully informed and have given written consent for the use of their data.
排除标准
- •Have received any prior treatment with pemetrexed
- •Are participating in a study including administration of any investigational drug or procedure at entry into this study
研究组 & 干预措施
Second-line pemetrexed treatment in NSCLC
Patients with NSCLC who will start second-line treatment with pemetrexed.
干预措施: Pemetrexed (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Chemotherapy in Treating Patients With Lung CancerNon Small Cell Lung CancerNCT01067794Eli Lilly and Company1,610
Unknown
不适用
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine KinaseNon-Small-Cell Lung CancerNCT02755337Dr. Soetomo General Hospital70
终止
2 期
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung CancerNon Small Cell Lung CancerNCT00509366Duke University101
招募中
不适用
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNon-small Cell Lung CancerNCT05363319Regeneron Pharmaceuticals500
Unknown
不适用
Factors Determining the Prognosis in NSCLC Stage IVNSCLC Stage IVNCT04306094Instituto do Cancer do Estado de São Paulo217